ENTROVAS 49mg+51mg Tablet contains Sacubitril 49 mg + Valsartan 51 mg. It is an angiotensin receptor-neprilysin inhibitor (ARNI) used for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Sacubitril increases beneficial natriuretic peptides, while Valsartan blocks the harmful effects of angiotensin II, helping improve heart function, reduce blood pressure, and decrease the workload on the heart.
Uses:
Treatment of chronic heart failure with reduced ejection fraction (HFrEF).
Reduces the risk of:
Cardiovascular death
Hospitalization due to heart failure
Helps improve symptoms such as:
Shortness of breath
Fatigue
Swelling of the legs and ankles
Reduced exercise capacity
Used as a replacement for an ACE inhibitor or ARB in appropriate patients as prescribed by a physician.
Dose:
Adults: Usually 1 tablet twice daily or as directed by a physician.
May be taken with or without food.
Swallow the tablet whole with water.
If switching from an ACE inhibitor, allow a 36-hour washout period before starting this medicine.
Regular monitoring of blood pressure, kidney function, and serum potassium is recommended during treatment.
Do not stop or change the dose without medical advice.